9月27日,施贵宝(BMY)股价盘前大涨6.15%,主要受到两大利好消息的推动。
首先,施贵宝旗下一款用于治疗精神分裂症的新药物获得美国FDA的批准上市,这意味着公司将在美国市场拥有一款新的经济增长点。该新药一旦在美国上市销售,预计将为施贵宝带来可观的药品收入,增强了投资者对公司中长期增长前景的信心,从而推升了股价。
与此同时,为缓解经济下行压力,中国央行决定降低金融机构存款准备金率0.5个百分点,并下调7天期逆回购操作利率20个基点。这一宽松货币政策利好股市整体情绪,也进一步支撑了施贵宝等中概股的表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.